Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy. 2022

Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
Oncology Unit, ASL 3, Villa Scassi Hospital, Corso Scassi 1, 16149 Genoa, Italy.

Information on immune responses in cancer patients following mRNA COVID-19 vaccines is still insufficient, but generally, patients had impaired serological responses, especially those with hematological malignancies. We evaluated serological response to COVID-19 mRNA vaccine in cancer patients receiving chemotherapy compared with healthy controls. In total, 195 cancer patients and 400 randomly selected controls who had been administered a Pfizer-BioNTech or Moderna COVID-19 vaccines in two doses were compared. The threshold of positivity was 4.33 BAU/mL. Patients were receiving anticancer treatment after the first and second dose of the vaccines. a TOTAL OF 169 patients (87%) had solid tumors and 26 hemolymphopoietic diseases. Seropositivity rate was lower in patients than controls (91% vs. 96%), with an age/gender-adjusted rate ratio (RR) of 0.95 (95% CL = 0.89-1.02). Positivity was found in 97% of solid cancers and in 50% of hemolymphopoietic tumors. Both advanced and adjuvant therapy seemed to slightly reduce seropositivity rates in patients when compared to controls (RR = 0.97, 95% CL = 0.89-1.06; RR = 0.94, 95% CL = 0.87-1.01). the response to vaccination is similar in patients affected by solid tumors to controls. On the contrary, hemolymphopietic patients show a much lower response than controls.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000087503 mRNA Vaccines Vaccines formulated with recombinant mRNAs which are taken up by the host cells that translate the mRNA and present the translated proteins to the immune system as antigens in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigen. Messenger RNA Vaccines,Naked RNA Vaccines,RNA Vaccines,Self-Amplifying RNA Vaccine,Trans Amplifying RNA Vaccine,saRNA Vaccine,taRNA Vaccine,RNA Vaccine,mRNA Vaccine,RNA Vaccine, Self-Amplifying,Self Amplifying RNA Vaccine,Vaccine, RNA,Vaccine, Self-Amplifying RNA,Vaccine, mRNA,Vaccine, saRNA,Vaccine, taRNA,Vaccines, RNA
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic

Related Publications

Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
April 2021, medRxiv : the preprint server for health sciences,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
November 2021, Cell & bioscience,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
October 2021, medRxiv : the preprint server for health sciences,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
September 2021, Microbiology spectrum,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
January 2022, Journal of nephrology,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
August 2021, Cancers,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
January 2024, medRxiv : the preprint server for health sciences,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
February 2021, Journal of genetics and genomics = Yi chuan xue bao,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
March 2022, Leukemia & lymphoma,
Manlio Mencoboni, and Vincenzo Fontana, and Azzurra Damiani, and Antonino Spitaleri, and Alessandro Raso, and Luigi Carlo Bottaro, and Giovanni Rossi, and Luciano Canobbio, and Antonella La Camera, and Rosa Angela Filiberti, and Paola Taveggia, and Alessia Cavo
August 2021, Cancer cell,
Copied contents to your clipboard!